Kite, a Gilead Sciences unit, announced Tuesday that it will acquire Tmunity Therapeutics and expand its pipeline with the biotech’s next-generation CAR T therapies and technologies. Kite didn’t ...
Kite, a Gilead unit, announced Tuesday afternoon that it has hired Cindy Perettie as EVP. In the position, Perettie will oversee the CAR-T unit’s cell therapy business, effective May 30. Most recently ...
During part of Cindy Perettie’s long run at Roche, the Swiss company put her in command of one of the industry's largest oncology portfolios. A few years later, Perettie will soon find herself running ...
Gilead Sciences is laying off about 7% of employees at cell therapy unit Kite Pharma in a restructuring it said is meant to better align the division’s organization with areas of future growth. About ...
Gilead Sciences’ cell therapy subsidiary, Kite, is acquiring Tmunity Therapeutics in a deal that brings preclinical and clinical-stage programs, technologies with potential applications in the next ...
May 2 (Reuters) - Gilead Sciences Inc, which hired Roche veteran Daniel O'Day to be its new chief executive, on Thursday said Kite Pharma, the cancer-focused cell therapy company it acquired in 2017, ...
AbbVie and National Institutes of Health (NIH) veteran Francesco Marincola, M.D., will become Gilead’s new head of cell therapy research out of its Kite unit. He replaces Peter Emtage, Ph.D., who quit ...
Gilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch of cell therapy products for solid tumours and blood cancers. The partnership covers up to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback